Introduction
A recent increase in the availability of designer drugs (also known as legal highs) in Ireland led to a legislative ban on these substances in May of 2010. The list of substances banned under the Misuse of Drugs Act include synthetic cannabinoids, piperazine derivatives relating to benzylpiperazine, cathinones mephedrone, methylone, methedrone, butylone, fluoromethcathinone and the solvent gamma-butyrolactone (GBL) (Figure 1 ). Although these substances have been withdrawn from the public since their ban, they still remain drugs of abuse in the illicit drug market in Ireland. The Drug Treatment Centre Board (DTCB) drug testing laboratory has previously described their prevalence in literature (1, 2) , and since the ban in 2010, they have continued to screen the urine of attendees of the DTCB and analyze external requests for these substances. This paper reports the development, validation and application of the screening method used for the identification and semi-quantification of 36 stimulants in urine by liquid chromatography -tandem mass spectrometry (LC -MS-MS).
The screening method includes three types of stimulant, namely, the substituted phenethylamines that include amphetamines and the substituted cathinones, the piperazines and alkaloids relating to cocaine. Other compounds not classified in the previously named groups, such as caffeine, fluorotropacocaine, desoxypipradol and dimethocaine, were included in the screen due to their prevalence in legal high products. LC-MS methods for these compounds, individually or as a class, are available in literature; however, there is a need for one method that can collectively identify and confirm all compounds.
Most recently, Bell et al. have developed an LC-MS method for the direct urinalysis of designer drugs (3) . This method was capable of analyzing eight substituted cathinones and substituted piperazines in one single screen. Most pharmacokinetic methods screen for the metabolites of such designer drugs because their concentrations in urine are normally higher than the parent compound (4, 5) . The lack of metabolite information and the time involved to prepare metabolite standards would cause significant delay in producing analytical methods. To expedite the screening and detection of the increasing number of designer drugs, only parent compounds are evaluated by this method. The high doses taken by users usually ensure sufficient levels in the urine to be detected. In this method, five identification parameters, namely, retention time, parent mass, a quantitative fragment mass, a qualitative fragment mass and an enhanced product ion mass spectrum, are used for the confirmation of the presence of a drug. The enhanced product ion (EPI) mass spectrum is generally used if there is any ambiguity in the previous identification parameters and is used as a final method of identification. The EPI generates an MS-MS fragmentation fingerprint that can be saved to library to allow automated identification.
There are many advantages to including these compounds in a single stimulant screen. It is necessary to study the prevalence of these known designer drugs within the drug-using community in Ireland. Drug users are knowingly using these designer drugs, but also find themselves unknowingly consuming them when popular stimulants such as amphetamine, ecstasy and cocaine are adulterated with designer drugs. It is important to identify new adverse affects that occur in patients who ingest these drugs in combination with other stimulant compounds. Poly-drug users may find synergistic effects between the numerous types of monoamine reuptake inhibitors, increasing the probability of an adverse event (6 -8) . This method can be used to confirm the presence of these stimulants in urine and to eliminate any erroneous result generated by clinical immunoassay techniques. Many of these designer drugs have the ability to cross-react with immunoassay methods for amphetamines. For example, metachlorophenylpiperazine (mCPP) has the ability to cause false positive urine amphetamine immunoassay results (9) , and cathinone, cathine and phenylpropanolamine have been shown to produce positive results in the Mahsan-AMP(300) on-site immunoassay (10).
Experimental

Materials
High-performance liquid chromatography (HPLC)-grade solvents were purchased from Fisher Scientific Ireland. All other reagents and buffers were purchased from Sigma-Aldrich Ireland. Standards, where available, were purchased from LGC Standards as certified reference materials. N, N-dimethylcathinone, 4-methylethcathinone (4-MEC), desoxypipradol, benzedrone, fluorotropacocaine and dimethocaine were obtained from head shops in Ireland as products containing other additives. These were purified and characterized by flash column chromatography, LC-MS and nuclear magnetic resonance (NMR) at Trinity College Dublin (11 -13) .
Instrumentation
Liquid chromatography was conducted on an Agilent 1100 series HPLC equipped with an Xterra RP18 100 Â 4.6 mm, 3.5 mm column fitted with an Xterra RP18 10 Â 4.6 mm guard column at 308C. The injection volume was 20 mL, run time was 11 min and the flow rate was 500 mL/min.
Mass spectrometry detection was conducted using an Applied Biosystems API 3200 Qtrap MS. Compounds were optimized on the mass spectrometer by an infusion of 100 ng/ mL solution in water at 5 mL/min, using the automated compound optimization wizard in Analyst software. The Q1, Q3 and MS parameters are listed in Table I . The dwell time for each quantitative and qualitative transition was 10 and 5 ms, respectively.
Methods
A stock LC -MS mobile phase buffer was prepared by dissolving 1.58 g of ammonium formate in 1,000 mL of deionized water with 5 mL formic acid (final concentration: 0.5% formic acid, 25 mM ammonium formate). This buffer was stored in the refrigerator and had an expiry of one month. Mobile phase A was prepared by mixing 100 mL of buffer with 100 mL of acetonitrile and 800 mL of water. Mobile phase B was prepared by mixing 100 mL of buffer with 900 mL of acetonitrile. The mobile phases were mixed and degassed by vacuum filtration. The LC gradient conditions were as follows, 0 % B for 1 min to 100 % B over 8 min, re-equilibrated at 0 % B for 2 min. An HPLC wash solution was prepared for injection between every sample by the addition of 100 mL of formic acid to 100 mL of methanol. This helped to prevent any carryover onto consecutive injections. Samples were prepared by centrifuging 1 mL of each urine sample (if necessary) to be analyzed at 4,000 rpm for 5 min. One hundred microliters of each urine sample supernatant were added to 900 mL of deionized water in an HPLC vial and vortex mixed for 3 s.
Results
All analytes with common mass transitions were separated from each other using the reversed-phase (RP)-HPLC method, with the exception of ethylone and butylone, which coelute by HPLC and contain the same quantitative and qualitative mass transitions. These compounds were validated independently; however, because they are indistinguishable from each other, they were reported as ethylone/butylone in some cases. A summary of the validation results is given in Table II . Linearity experiments were performed in triplicate. The linear range for all compounds was at least 5 -50 ng/mL in 10% urine in a water solution. Compounds such as ethylecgonine and 5,6-methylenedioxy-2-aminoindane (MDAI) had a higher linear range, 2,500 ng/mL in neat urine samples. The correlation coefficient for all linear curves was .0.98. The limit of quantitation (LOQ) was determined as the minimum concentration in prepared urine samples that gave a signal 10 times greater than the signal-to-noise ratio. This was calculated at the minimum concentration on the linear curve, representing an LOQ of 50 ng/mL for each analyte in neat urine. The matrix effect on each analyte was assessed by determining the linear range in water solutions and in 10% urine solutions. The slope of the equations of the lines of both linear curves was proportional to the response of analyte in each solution. The slope of linear curve of the 10% urine solution divided by the slope of the linear curve of the water solution was a measure of the matrix effect on each analyte. A value greater than 1.00 indicated enhancement of the signal and a value less than 1.00 indicated ion suppression.
3,4-Methylenedioxypyrovalerone (MDPV) was particularly affected by ion suppression, with a signal approximately 20% of that in 10% urine solution than in water. Although some cathinones such as MDPV, methedrone, buphedrone and naphyrone suffered from signal suppression, there was no particular trend across the group of cathinones, and compounds such as 3,4-methylenedioxypyrrolidinobutyrophenone (MDPBP) and ethylone/butylone showed enhanced signals. Caffeine and 3-trifluoromethylphenylpiperazine (TFMPP) also suffered from ionisation suppression in urine solution. The compound that had the highest signal enhancement was 3,4-methylenedioxyamphetamine (MDA), in which the signal showed 221% enhancement in a 10% urine solution than water alone. There are potentially co-eluting components in the urine that cause the elevated or enhanced suppression of ionization, which may be removed by sample pretreatment techniques such as solid-phase extraction. The ease of sample preparation with the dilute and shoot technique and adequate limits of detection (LODs) negated the need for further sample pretreatment.
During the period from September to December, 2010, 155 urine samples were analyzed and 66 (43%) tested positive in the stimulant screen (Figure 2 ). Substituted cathinones were identified in 54% of the positive cases. Cocaine was the most prevalent drug, whereas mephedrone, benzylpiperazine (BZP), TFMPP, MDPV and MDPBP were the most widely used legal highs. From January to August, 2011, 199 (68%) of 294 analyzed urine samples were found to be positive (Figure 3) . Substituted cathinones were identified in 25% of the positive cases and MDPBP was found to be the most prevalent. The piperazines accounted for only 3% of total positive samples. The decrease in cathinones and piperazine usage was due to the legislative ban in 2010. Twenty-eight positives (14%) were found to contain more than one drug, the majority of these being cathinones/cocaine, cathinones/amphetamines and BZP/TFMPP. Combinations of desoxypipradol/cocaine, 3,4-methylenedioxymethamphetamine (MDMA)/cocaine, fluorotropacocaine/MDPBP or dimethocaine/MDPBP were also found. One sample was found to contain seven stimulants, which included piperazines, amphetamines and cocaine.
Discussion
Method development
An RP-HPLC gradient method was selected as the separation mode. Two aqueous mobile phases were evaluated, containing 2.5 mM ammonium formate-0.05% NH 4 OH and 2.5 mM ammonium formate-0.05% formic acid. The organic modifier was acetonitrile. The peak shape was evaluated by analyses of peak symmetry and tailing factor. The minimum resolution between two peaks with same nominal mass transitions was 1.5. The earliest eluting peak was ethylecgonine at 2.3 min and the latest eluting peak was naphyrone at 8.4 min. The minimum peak width was approximately 0.2 min (12 s). The average total scan time on the mass spectrometer was approximately 1.4 s, which correlates to approximately eight data points across each peak; this was regarded as suitable for this semiquantitative confirmatory method.
Three column types were evaluated: Gemini C18, Xterra RP18 and Allure PFP Propyl. The Allure PFP Propyl column yielded inadequate resolution between cathinones with same nominal mass. The Gemini C18 column yielded poor peak shape for piperazine type compounds and some primary amines, the likely reason being that the piperazines contain two amino groups, and the primary amines are more polar than other compounds. The Gemini C18 could possibly have more residual silanol groups, which interact strongly with more polar analytes. The Xterra RP18 column had good peak shape and resolution between all compounds, and this was selected as the analytical column. The high pH ( pH 10) aqueous mobile phase resulted in longer retention times and better peak shape due to deprotonation of charged amines, but the low pH of the method ( pH 3) had faster analysis times with adequate retention, so this was chosen as the aqueous mobile phase buffer. The gradient was optimized by running two linear scouting gradients at 308C, one 5 -95% B over 20 min and the other 5 -95% B over 60 min. The retention times, peak areas, peak width and tailing factors of all analytes were input into Drylab software and the optimum gradient was simulated. This simulated optimized gradient was reproducible on the HPLC system and the system suitability was established.
Method validation
The linear range of the method was evaluated by injecting a range of standards diluted in drug-free urine, usually at least two orders of magnitude in range. This was performed with each analyte in the concentration range 5 -500 ng/mL. The linear range was determined as the portion of the line that gave a linear regression correlation coefficient r . 0.98. Concentration levels that caused linear deviation outside r . 0.98 were omitted. Only the first transition was evaluated for each analyte for linearity, because this was the most abundant transition and was used for quantitative analysis. The second transition was used for qualitative confirmation. Linearity experiments were performed in triplicate. The injection precision was evaluated by repeated injections of the same standard solution. For example, each linearity standard solution was injected three times. The precision in the mass spectrometer is particularly dependent on ion dwell time. Increasing the dwell time on the method will increase the precision of the analysis, but will also increase the total scan, which will lead to poor integration and fewer sample points across each peak. System suitability was evaluated by repeat injection of a quality control (QC) standard. For example, the 100 ng/mL QC standard was injected five times. The system was suitable before analysis if the retention times of the analytes were constant, the injection precision was acceptable and each transition per analyte was obtained in the mass spectrometer. This check was performed before all analyses to verify that the LC and MS systems were functioning adequately. The QC sample was also injected after analysis to bracket samples that had been run to ensure that system suitability was maintained throughout the run. An example of the QC chromatography obtained for selected ions is demonstrated in Figure 5 . Sample carryover was evaluated by injecting a blank solution after the highest standard on the linearity evaluation, 500 ng/mL. This blank was subsequently analyzed for carryover. The wash vial contained 0.1% formic acid in methanol. No carryover was detected above the LOQ. The LOQ was evaluated as the lowest signal that produced a peak with a signal-to-noise ratio . 10. For each analyte, the lowest concentration level, 5 ng/mL, produced a peak with signal-to-noise ratio . 10. At the lowest level, where the precision was poor, the LOQ was increased to 10 ng/mL. Matrix effects were evaluated by comparing the slopes of the linearity curves of two sets of standards. MDPV, TFMPP and caffeine suffer from the worst matrix effects.
Testing results
This screening method commenced in September 2010 and continued to the end of the year. During this time, 155 requests for confirmatory stimulant screens were placed by doctors treating patients in the DTCB. As the screening process developed further, additional compounds such as pseudoephedrine, desoxypipradol, MDMA, flurotropacocaine, amphetamine, MDA, dimethocaine, methamphetamine and 3,4-methylenedioxy-N-ethylamphetamine (MDEA) were added.
One of the findings from these screens was that the most prevalent substituted cathinone utilized by patients attending the DTCB was mephedrone. This correlates with the mephedrone found in products sold in head shops during this time period (Table III) . Several reports in the EU also showed that there was a current instability in the ecstasy market, especially in 2009, and that mephedrone was replacing MDMA in tablets seized as ecstasy (14) . Potentially, MDMA users in Ireland were unknowingly ingesting or using mephedrone during this time. The toxicity of mephedrone has widely been investigated (15) (16) (17) (18) (19) , and commonly reported clinical features include agitation or aggression, tachycardia, confusion or psychosis, chest pain, nausea, palpitations, peripheral vasoconstriction and headache. Many deaths have also been reported (18) . The mephedrone found in four deceased people had levels in femoral venous blood ranging from 0.13 -2.24 mg/L. Two of the deaths were attributed solely to mephedrone use and one was found to have co-administered other narcotics such as methadone and prescription medications. Mephedrone is metabolized to at least five known phase I metabolites (20) , all of which contain the amino group moiety, and therefore, would all be expected to contribute to its neuropharmacological profile. The major metabolic pathways are N-dealkylation, reduction and hydroxylation. The pharmacological and toxicological effects have been extensively reviewed by Dargan et al. (21) . These data demonstrated that mephedrone has a unique pharmacological profile with both abuse liability and neurotoxic potential (22) .
In 2010, the screening results indicate that substituted cathinones accounted for 54% of positive stimulant screen results, indicating their wide availability and abuse ( Figure 2) . All of the substituted cathinones are likely to behave neuropharmacologically similar, because they contain the same basic alpha-amino ketone pharmacophore. From the perspective of chemistry, there are two significant problems with alpha-amino ketones: they are generally unstable and they are known pro-oxidants (23) . This has implications about the synthesis, storage and stability of these substituted cathinones. Although there is no literature available on the stability of these specific compounds, bupropion, which is the only legal alpha amino-ketone, has been widely studied and can be used as a model. Bupropion is prone to base-catalyzed hydrolysis and oxidation (24) . These amino-ketones are likely to suffer the same stability issues (Figure 4) . Their ability to tautomerise leads to the enol/enamine form, which can tautomerise again to the unstable imine form. This leads to loss of the alkylamine group through hydrolysis, leading to neutral and acidic impurities, as shown in the degradation of bupropion. These neutral degradants, although not containing the amino group and rendered neurpharmacologically inactive, would pose significant health effects due to their high lipophilicity and ability to accumulate in fatty tissues. Certain degradation products, alpha-dicarbonyl compounds, have been hypothesized to participate in deleterious biological processes, particularly in aging (25) . It is also a likely inhibitor of carboxylesterase (26) . Two other degradation products of these cathinones are the alpha hydroxy-ketones. These alpha hydroxy-ketones are likely to be pharmacologically active as urease inhibitors (27) and are known to oxidize to the alpha dicarbonyl compound. The significance of the stability problem of these cathinones is a concern, and further work is needed to establish the levels of these types of degradants in seized cathinone products.
From January to August of 2011, approximately 294 requests were made for stimulant screens in the authors' laboratory; the positive results are shown in Figure 3 . The banning of these cathinones is evident by a 25% decrease in total positive samples containing the substituted cathinones. One significant change in the positive results since the legislative ban is the emergence of MDPBP as the most widely abused substituted cathinone. Very little is known about MDPBP and the literature is sparse. It has been found in legal highs in the United Kingdom (28) and has been characterized spectroscopically (29) , but there is an absence of any pharmacological, toxicological or pharmacokinetic data. It contains the pyrrolidinophenone pharmacophore, and is therefore similar to MDPV and such types. CYP2D6 is the major enzyme, catalyzing the major metabolic steps of the studied pyrrolidinophenone-derived designer drugs (30) , and this metabolism has been studied (31) . MDPBP is likely to be more potent than mephedrone due to its higher lipophilicity and ability to more readily cross the blood brain barrier.
The piperazines related to BZP are mCPP and TFMPP. BZP predominantly affects dopamine neurotransmission, in a fashion similar to known drugs of abuse such as methamphetamine and cocaine (32) . The piperazine derivatives and BZP have been studied extensively in literature (33) . These compounds can cause harmful effects when taken recreationally, with commonly reported side effects such as palpitations, agitation, anxiety, confusion, dizziness, headache, tremor, mydriasis, insomnia, urine retention and vomiting. Seizures are induced in some patients, even at low doses. Severe multiorgan toxicity has been reported, although fatalities have not been conclusively recorded (8) . The piperazines, BZP and TFMPP represented a significant portion of positive stimulant screen results in 2010, accounting for 14% of positives. In most cases, both piperazines were found in combination, and this was evident from products sold as party pills (7) . Taken together, they have been reported to produce a high similar to that produced by MDMA (6) . BZP showed significant dexamphetamine-like stimulant effects, inducing euphoria, sociability and drug liking, whereas TFMPP induced fewer stimulantlike effects and increased anxiety via its serotonergic effects.
The combination of BZP and TFMPP induced similar subjective effects, along with well-characterized dexamphetamine-like and MDMA-like effects. These subjective data allow for obvious comparisons to be made between party pill drugs and other commonly known stimulants.
Cocaine is one of the most widely abused stimulants worldwide and is known to be co-administered with legal highs by users (17) . Cocaine and its alkaloid metabolites were thus included in the stimulant screen. Ethylecgonine was included to determine whether cocaine had been consumed with alcohol, and methylecgonidine, the pyrolysis product of cocaine, was included to determine whether cocaine was consumed by smoking crack cocaine.
Fluorotropacocaine ( pFBT) and dimethocaine are synthetic cocaine derivatives. The structure of pFBT is closely related to that of cocaine, however, dimethocaine lacks a tropane ring and more closely resembles the structure of procaine, a local anaesthetic drug without psychoactive properties. Therefore, there is some doubt as to whether dimethocaine itself has psychoactive effects in humans. These substances have been found in legal high products in Ireland called Mind Melt and were thus included in the screen. Little is known about the detailed pharmacokinetics and pharamacodynamics of these substances in humans. Apart from any central nervous system activity, both act as local anesthetics.
Two other local anesthetics included in the screen were benzocaine and lidocaine. Both of these anesthetics are known to be included in legal highs seized in the UK (34) and in head shop samples obtained in Ireland (Table III) . Legal highs such as Wild Cat, Blow, White Ice, Oceanic Deeper, Charge and Sextacy have all been shown to include combinations of substituted cathinones and anaesthetics. They are used in combination with stimulants to mimic the effects of cocaine on users.
Ten positive samples of the 66 positive patient requests in 2010 were shown to have more than one stimulant in the urine screen. The most abundant types of poly-drug abuse were shown to have combinations of different cathinones present, likely from the different head shop products available at the time. These products may have been mixtures of different cathinones, or possibly, different products were ingested at one time. The second most frequent poly-drug abuse in 2010 came from combinations of BZP and TFMPP, which are usually obtained as a mixture in products. In 2011, 28 positive samples of the 199 positive patients tested were shown to have more than one stimulant in their urine. The majority of these were combinations of cathinones and cocaine, cathinones and amphetamines and BZP/TFMPP. Desoxypipradol was observed in combination with cocaine. Flurotropacocaine was observed in combination with MDPBP and cocaine on several occasions. MDMA and cocaine were observed in combination quite frequently, but also seen with cathinones. Dimethocaine and MDPBP were observed in combination on several occasions. Whether these combinations were ingested knowingly or unknowingly from adulterated illicit products, the abundance of poly-drug use illustrates the importance of future study into these stimulant combinations. The likelihood of adverse effects relating to synergistic pharmacological combinations is an area of study still in its infancy as these designer drugs emerge. This method can be utilized to screen for these combinations in drug users. 
Conclusions
The authors' laboratory has developed and validated a confirmatory method for screening stimulants in urine by LC-MS analysis. The combination of known stimulants and designer drugs included in the screen has merit in studies such as immunoassay cross reactivity, studies of adverse effects contributed to designer drugs and studies on the effects of administering combination stimulants. This method was used to evaluate stimulant drug usage in attendees of the DTCB in Ireland in 2010 and 2011. Substituted cathinones are a significant problem, comprising 54% of positive results in 2010 and 25% of positive results in 2011. The increasing number of dangerous designer drugs emerging each year represents an ongoing analytical challenge due to legislative difficulties and the lack of reference standards.
